FDA Approves New Diabetes Drug

The US Food and Drug Administration recently approved Ozempic (semaglutide) as an adjunct to diet and exercise for the improvement of glycemic control in adult patients with type 2 diabetes.

Ozempic is a glucagon-like peptide-1 receptor antagonist and is administered as an injection once a week at a dose of either 0.5 mg or 1 mg.
__________________________________________________________________________
RELATED CONTENT
FDA Approves Once-Weekly Diabetes Option
Diabetes Drug Lowers Stroke Risk 
__________________________________________________________________________

Approval was based on the results from the SUSTAIN clinical trial, which showed clinically meaningful and statistically significant reductions in glycated hemoglobin among patients who had received Ozempic compared with those who had received placebo, sitagliptin, exenatide extended-release, or insulin glargine U100. In addition, patients who had received Ozempic experienced significant reductions in body weight.

The most common adverse effect associated with Ozempic was mild to moderate nausea.

—Melissa Weiss

Reference:

Ozempic® (semaglutide) approved in the US [press release]. Bagsværd, Denmark: Novo Nordisk, December 5, 2017. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2154210.html. Accessed December 5, 2017.